CHF Solutions, Inc.
7601 Northland Drive
12 articles with CHF Solutions, Inc.
1/22/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
CHF Solutions Initiates Strategic Collaboration with Daxor Corporation to Assist in the Management of Patients with Fluid Overload
CHF Solutions, Inc. (Nasdaq: CHFS) announced today that it has entered into a collaboration agreement with Daxor Corporation (NYSE:DXR) to explore potential synergies between the company’s Aquadex FlexFlow® System and Daxor’s BVA-100 Blood Volume Analyzer.
11/22/2017The Series F preferred stock is convertible into shares of the company’s common stock at a conversion price of $4.50 per share.
CHF Solutions’ Aquadex Flexflow Aquapheresis System Receives FDA IDE Approval For Clinical Study For Pediatric Use
Latest American College of Cardiology/American Heart Association Treatment Guidelines for Heart Failure Recommend American College of Cardiology's Ultrafiltration Therapy
CHF Solutions, Inc. Release: Seven Studies on Ultrafiltration Presented at Heart Failure Society of America Annual Meeting
CHF Solutions, Inc. Release: Five Studies On Aquapheresis™ Therapy Presented At Heart Failure Society Of America Annual Meeting
CHF Solutions, Inc. Release: Ultrafiltration's Immediate And Long-Term Benefits Demonstrated In Heart Failure Patients